Marjolaine Gauthier-Loiselle
Analysis Group
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marjolaine Gauthier-Loiselle.
Clinical Genitourinary Cancer | 2017
William Oh; Raymond Miao; Francis Vekeman; Jennifer Sung; Wendy Y. Cheng; Marjolaine Gauthier-Loiselle; Ravinder Dhawan; Mei Sheng Duh
Background In metastatic castration‐resistant prostate cancer (mCRPC), optimal treatment sequences are unknown. We assessed second‐line taxane (TT) versus androgen receptor‐targeted therapy (ART), after initial ART failure, in United States oncology community practices. Patients and Methods Using electronic medical records, patients with mCRPC receiving first‐line ART and second‐line therapy (TT, ART) were identified. Response and overall survival (OS) were evaluated from second‐line therapy initiation. Multivariate analyses were adjusted for year, age, metastases, opioid use, prostate‐specific antigen (PSA), hemoglobin, alkaline phosphatase, and albumin levels. Results Of 546 patients receiving first‐line ART, 206 and 340 received second‐line TT and ART. Compared with patients receiving second‐line ART, patients receiving TT were younger (median, 74 vs. 79 years), more had intermediate‐high Halabi risk scores (59% vs. 35%), had higher opioid use (42% vs. 22%), median PSA (116 vs. 48 ng/mL), alkaline phosphatase (112 vs. 87 U/L), and lactate dehydrogenase (254 vs. 201 U/L), and had lower hemoglobin (11.2 vs. 12.3 g/dL) and albumin levels (3.8 vs. 4.0 g/dL); all P < .001. Response rates were higher with second‐line TT versus ART (clinical response, 44.2% vs. 24.7%; P = .006; PSA response, 44.5% vs. 28.7%; P = .004). OS did not differ between cohorts (hazard ratio [HR], 0.90; P = .511). Among patients with a poor prognosis (hemoglobin < 11 g/d; albumin < lower limit of normal), those receiving second‐line TT versus ART showed improved OS (HR, 0.52; P = .004 and HR, 0.36; P = .003, respectively). Conclusions Despite more severe disease profiles, patients with mCRPC receiving second‐line TT versus ART achieved higher response rates after initial ART. Poor prognosis patients had improved OS with second‐line TT versus ART. Microabstract Optimal treatment sequences for metastatic castration‐resistant prostate cancer are unknown. This retrospective study assessed outcomes in patients with metastatic castration‐resistant prostate cancer receiving second‐line taxane chemotherapy versus second‐line androgen receptor‐targeted therapy (ART), after failure of first‐line ART, in a real‐world setting. In patients who have previously recieved ART, second‐line taxane chemotherapy, versus alternative ART, may be associated with improved outcomes, particularly among patients with a worse disease prognosis.
Journal of The American Academy of Dermatology | 2018
Jashin J. Wu; Murali Sundaram; Martin Cloutier; Marjolaine Gauthier-Loiselle; Annie Guerin; Rakesh Singh; Arijit Ganguli
Background: Psoriasis is a risk factor for cardiovascular events. Objective: To assess the risk of major cardiovascular events and the effect of cumulative treatment exposure on cardiovascular event risk in patients with psoriasis treated with tumor necrosis factor–&agr; inhibitors (TNFis) versus phototherapy. Methods: Adult patients with psoriasis were selected from a large US administrative claims database (from the first quarter of 2000 through the third quarter of 2014) and classified in 2 mutually exclusive cohorts based on whether they were treated with TNFis or phototherapy. Cardiovascular event risk was compared between cohorts using multivariate Cox proportional hazards models. Cumulative exposure was defined based on treatment persistence. Results: A total of 11,410 TNFi and 12,433 phototherapy patients (psoralen plus ultraviolet A light phototherapy, n = 1117; ultraviolet B light phototherapy, n = 11,316) were included in this study. TNFi patients had a lower risk of cardiovascular events compared to phototherapy patients (adjusted hazard ratio 0.77, P < .05). The risk reduction associated with 6 months of cumulative exposure was 11.2% larger for patients treated with TNFis compared to phototherapy (P < .05). Limitations: Information on psoriasis severity and mortality was limited/not available. Conclusions: Patients with psoriasis who were treated with TNFis exhibited a lower cardiovascular event risk than patients treated with phototherapy. Cumulative exposure to TNFis was associated with an incremental cardiovascular risk reduction compared to phototherapy.
Ajidd-american Journal on Intellectual and Developmental Disabilities | 2015
Francis Vekeman; Marjolaine Gauthier-Loiselle; Elizabeth Faust; Patrick Lefebvre; Raquel Lahoz; Mei Sheng Duh; Patricia Sacco
This study evaluated the incremental healthcare costs associated with Fragile X syndrome (FXS) for patients and their caregivers. Using administrative healthcare claims data (1999-2012), subjects with ≥ 1 FXS diagnosis (ICD-9-CM: 759.83) were matched 1:5 with non-FXS controls using high-dimensional propensity scores. Costs and resource utilization were examined. Among employees, payment for disability leave and absenteeism were also examined. We identified 590 FXS and 2,950 non-FXS individuals along with 647 and 2,611 caregivers, respectively. FXS patients and their caregivers experienced higher all-cause direct costs compared to control cohorts (total[SD]:
Leukemia & Lymphoma | 2018
Richard T. Maziarz; Yanni Hao; Annie Guerin; Geneviève Gauthier; Marjolaine Gauthier-Loiselle; Simu K. Thomas; Lamis Eldjerou
14,677[46,752] vs.
Annals of the American Thoracic Society | 2016
Richard H. Stanford; Arpita Nag; Douglas W. Mapel; Todd A. Lee; Richard Rosiello; Francis Vekeman; Marjolaine Gauthier-Loiselle; Mei Sheng Duh; J. F. Philip Merrigan; Michael Schatz
6,103[26,081];
PLOS ONE | 2018
William Wong; Yeun Mi Yim; Ashley Kim; Martin Cloutier; Marjolaine Gauthier-Loiselle; Patrick Gagnon-Sanschagrin; Annie Guerin
5,259[19,360] vs.
Urologic Oncology-seminars and Original Investigations | 2018
William Oh; Wendy Y. Cheng; Raymond Miao; Francis Vekeman; Marjolaine Gauthier-Loiselle; Mei Sheng Duh; Edward Drea; Ted P. Szatrowski
2,120[6,425], respectively, p < 0.05). Employed FXS patients and caregivers had higher indirect costs compared to their controls (total[SD]:
Cancer Research | 2015
Christopher Gallagher; Kenneth More; Anthony Masaquel; Tripthi Kamath; Annie Guerin; Raluca Ionescu-Ittu; Marjolaine Gauthier-Loiselle; Roy Nitulescu; Nicholas Sicignano; Brian Barnett; Eric Q. Wu
4,477[5,161] vs.
SpringerPlus | 2016
Christopher Gallagher; Kenneth More; Anthony Masaquel; Tripthi Kamath; Annie Guerin; Raluca Ionescu-Ittu; Roy Nitulescu; Marjolaine Gauthier-Loiselle; Nicholas Sicignano; Elizabeth Butts; Eric Q. Wu; Brian Barnett
1,751[2,556];
Breast Cancer Research and Treatment | 2016
Christopher Gallagher; Kenneth More; Tripthi Kamath; Anthony Masaquel; Annie Guerin; Raluca Ionescu-Ittu; Marjolaine Gauthier-Loiselle; Roy Nitulescu; Nicholas Sicignano; Elizabeth Butts; Eric Q. Wu; Brian Barnett
2,641[4,238] vs.